Cargando…

TIM-3 Is a Potential Immune Checkpoint Target in Cats with Mammary Carcinoma

SIMPLE SUMMARY: Feline mammary carcinomas are highly prevalent tumors, with aggressive behavior and scarce therapeutic options. Thus, there is a high need for novel biomarkers and therapeutic targets. In human medicine, immune checkpoint inhibitors targeting TIM-3 are emerging as promising treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valente, Sofia, Nascimento, Catarina, Gameiro, Andreia, Ferreira, João, Correia, Jorge, Ferreira, Fernando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856819/ https://www.ncbi.nlm.nih.gov/pubmed/36672332 http://dx.doi.org/10.3390/cancers15020384

Ejemplares similares

The Landscape of Tumor-Infiltrating Immune Cells in Feline Mammary Carcinoma: Pathological and Clinical Implications
por: Nascimento, Catarina, et al.
Publicado: (2022)

Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma
por: Gameiro, Andreia, et al.
Publicado: (2021)

VISTA Is a Diagnostic Biomarker and Immunotherapy Target of Aggressive Feline Mammary Carcinoma Subtypes
por: Gameiro, Andreia, et al.
Publicado: (2021)

Anaplastic Mammary Carcinoma in Cat
por: Soares, Maria, et al.
Publicado: (2021)

Diagnostic Value of VEGF-A, VEGFR-1 and VEGFR-2 in Feline Mammary Carcinoma
por: Nascimento, Catarina, et al.
Publicado: (2021)

HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models
por: Gameiro, Andreia, et al.
Publicado: (2021)

Clinical Relevance of the serum CTLA-4 in Cats with Mammary Carcinoma
por: Urbano, Ana Catarina, et al.
Publicado: (2020)

Serum and Tissue Expression Levels of Leptin and Leptin Receptor Are Putative Markers of Specific Feline Mammary Carcinoma Subtypes
por: Gameiro, Andreia, et al.
Publicado: (2021)

Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes
por: Nascimento, Catarina, et al.
Publicado: (2020)

Emerging Biomarkers and Targeted Therapies in Feline Mammary Carcinoma
por: Gameiro, Andreia, et al.
Publicado: (2021)

Histone Deacetylase Inhibitors and Microtubule Inhibitors Induce Apoptosis in Feline Luminal Mammary Carcinoma Cells
por: Almeida, Filipe, et al.
Publicado: (2021)

Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status
por: Soares, Maria, et al.
Publicado: (2016)

CXCR4 and its ligand CXCL12 display opposite expression profiles in feline mammary metastatic disease, with the exception of HER2-overexpressing tumors
por: Marques, Cláudia S., et al.
Publicado: (2018)

HER2-positive feline mammary carcinoma
por: Marques, Cláudia, et al.
Publicado: (2016)

Gene expression association study in feline mammary carcinomas
por: Ferreira, Daniela, et al.
Publicado: (2019)

B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy
por: Tian, Xinyu, et al.
Publicado: (2023)

Paraneoplastic neutrophilic leukocytosis syndrome in a cat with recurrent mammary carcinoma
por: Jark, Paulo C, et al.
Publicado: (2015)

Serum SDF-1 levels are a reliable diagnostic marker of feline mammary carcinoma, discriminating HER2-overexpressing tumors from other subtypes
por: Marques, Cláudia S., et al.
Publicado: (2017)

Glycoproteomic landscape and structural dynamics of TIM family immune checkpoints enabled by mucinase SmE
por: Chongsaritsinsuk, Joann, et al.
Publicado: (2023)

Glycoproteomic landscape and structural dynamics of TIM family immune checkpoints enabled by mucinase SmE
por: Chongsaritsinsuk, Joann, et al.
Publicado: (2023)

CXCL12-CXCR4 axis in feline mammary carcinoma
por: Ferreira, Fernando
Publicado: (2017)

Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model
por: Sirait-Fischer, Evelyn, et al.
Publicado: (2020)

Immune regulation by Tim-3
por: Banerjee, Hridesh, et al.
Publicado: (2018)

Immune Checkpoint Receptors Tim-3 and PD-1 Regulate Monocyte and T Lymphocyte Function in Septic Patients
por: Xia, Qi, et al.
Publicado: (2018)

Modulation of the Gal-9/TIM-3 Immune Checkpoint with α-Lactose. Does Anomery of Lactose Matter?
por: Bailly, Christian, et al.
Publicado: (2021)

Assessment of ERBB2 and TOP2α gene status and expression profile in feline mammary tumors: findings and guidelines
por: Ferreira, Daniela, et al.
Publicado: (2019)

Proposal for a Histological Staging System of Mammary Carcinomas in Dogs and Cats. Part 2: Feline Mammary Carcinomas
por: Chocteau, Florian, et al.
Publicado: (2019)

Proposal for a Histological Staging System of Mammary Carcinomas in Dogs and Cats. Part 1: Canine Mammary Carcinomas
por: Chocteau, Florian, et al.
Publicado: (2019)

TIM-3: a tumor-associated antigen beyond checkpoint inhibition?
por: Barth, Stefan, et al.
Publicado: (2022)

fHER2, PR, ER, Ki-67 and Cytokeratin 5/6 Expression in Benign Feline Mammary Lesions
por: Soares, Maria, et al.
Publicado: (2022)

Genetic polymorphisms of immune checkpoint proteins PD-1 and TIM-3 are associated with survival of patients with hepatitis B virus-related hepatocellular carcinoma
por: Li, Zhu, et al.
Publicado: (2016)

Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma
por: Popp, Felix C., et al.
Publicado: (2021)

Differences in Immune Checkpoints Expression (TIM-3 and PD-1) on T Cells in Women with Recurrent Miscarriages—Preliminary Studies
por: Zych, Michał, et al.
Publicado: (2021)

TIMs: central regulators of immune responses
por: Hafler, David A., et al.
Publicado: (2008)

Correction to: TIM-3: a tumor-associated antigen beyond checkpoint inhibition?
Publicado: (2023)

The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?
por: Ganjalikhani Hakemi, Mazdak, et al.
Publicado: (2020)

Mammary Carcinoma Cell Derived Cyclooxygenase 2 Suppresses Tumor Immune Surveillance by Enhancing Intratumoral Immune Checkpoint Activity
por: Markosyan, Nune, et al.
Publicado: (2013)

Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion
por: Bruss, Christina, et al.
Publicado: (2023)

Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma
por: Li, Zhu, et al.
Publicado: (2016)

A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases
por: Nygaard, Vigdis, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ngb54bs4s30sau1rl318605691